Atsena Therapeutics, Inc.
ATSN-101, an AAV-based gene therapy for Leber congenital amaurosis type 1
- Sector
- Biotech
- Headquarters
- NC
- Founded
- 2019
- Latest Form D
- $90M, Apr 2025
- Total capital
- $147M
- Federal grants
- $871K
- 1 award · 2025
- Rank in peer group#145 of 326
- Private capital raised
- $146M
- 4 Form D · last Apr 2025
- 19 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 6 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1$871K
- Private capital raisedForm D · SEC · 4th filing$90M
- Private capital raisedForm D · SEC · 3rd filing$24.5M
- Private capital raisedForm D · SEC · 2nd filing$27.5M
- Private capital raisedForm D · SEC · 1st filing$4.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#145 · top 44%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Benjamin YerxaDirectorNamed in SEC Form D filings
- Chris CarpenterDirectorNamed in SEC Form D filings
- Christina IsacsonDirectorNamed in SEC Form D filings
- Elizabeth LeidermanExecutive OfficerNamed in SEC Form D filings
- Jacqueline GrantDirectorNamed in SEC Form D filings
- James HealyDirectorNamed in SEC Form D filings
Show all 13 people
- Jennifer WellmanDirectorNamed in SEC Form D filings
- Joe ZakrzewskiDirectorNamed in SEC Form D filings
- Michael DialDirectorNamed in SEC Form D filings
- Norbert RiedelDirectorNamed in SEC Form D filings
- Patrick RitschelExecutive Officer, DirectorNamed in SEC Form D filings
- Sanford BoyeExecutive OfficerNamed in SEC Form D filings
- Shannon BoyeExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 6- PendingAav Transfer PlasmidsUSPTOApplication 18291470
- PendingDual Aav Vectors For Treating Stargardt DiseaseUSPTOApplication 19480459
- PendingMethods For Treating XlrsUSPTOApplication PCTUS2025051353
Show all 6 patent records
- Aav Transfer PlasmidsMar 27, 2025 · Application 18291470Pending
- Dual Aav Vectors For Treating Stargardt DiseaseApplication 19480459Pending
- Methods For Treating XlrsApplication PCTUS2025051353Pending
- Dual Aav Vectors For Treating Stargardt DiseaseApplication 63499482Pending
- Aav Transfer PlasmidsApplication PCTUS2022038520Pending
- Aav Transfer PlasmidsApplication 63226410Pending
Related companies, and why
- CRYSTAL BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- Novelmed Therapeutics IncSimilar federal contract value in Biotech · null in contracts
- SAB Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- RNA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- APERTURE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Converge Bio Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .